Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells

While chemotherapy remains to be one of the main approaches in the clinical treatment of acute myeloid leukemia (AML), multidrug resistance (MDR) has become a serious problem which limits the therapeutic efficacy. The important roles of the PI3K/Akt pathway in modulating cell proliferation and MDR suggest that PI3K inhibitor might be effective for treatment of AML. In the present study, the antiproliferative effects of PI3K inhibitor ZSTK474 on AML cell HL60 and the adriamycin (ADR)-resistant HL60/ADR cells were investigated. Our data indicated that ZSTK474 exhibited potent antiproliferative activity, induced G1 cell cycle arrest, but no obvious apoptosis in both cell lines. Moreover, ZSTK474 affected the protein levels of cell-cycle-related molecules including increased p27, decreased cyclin D1 and phosphorylated Rb in dose-dependent manner. The proteins downstream of PI3K including phosphorylated PDK1, Akt and GSK-3β were reduced in a dose-dependent manner after ZSTK474 treatment. ZSTK474 reversed ADR resistance, increased the intracellular accumulation of ADR, and reduced the expression and function of multidrug resistance (MDR) proteins including both P-gp and MRP1 in HL60/ADR cells. The combination of ZSTK474 and chemotherapeutic drugs cytarabine or vincristine led to a synergistic effect in HL60 and HL60/ADR cells. In conclusion, ZSTK474 showed potent antiproliferative effect on HL60 and HL60/ADR cells; combination with cytarabine or vincristine resulted in synergistic effect. Our results suggest ZSTK474 has the potential to be applied in the treatment of AML patients, while further evidences particularly those about in vivo efficacy are needed.

[1]  You-jie Li,et al.  Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway. , 2016, Oncology reports.

[2]  Xing-chen Wei,et al.  Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells. , 2016, Biochemical and biophysical research communications.

[3]  You-jie Li,et al.  Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway. , 2016, International journal of oncology.

[4]  Xuening Wang,et al.  The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts , 2016, Oncotarget.

[5]  W. Yuan,et al.  Asclepiasterol, a novel C21 steroidal glycoside derived from Asclepias curassavica, reverses tumor multidrug resistance by down-regulating P-glycoprotein expression , 2016, Oncotarget.

[6]  T. Kawamata,et al.  Vincristine-induced paralytic ileus during induction therapy of treatment protocols for acute lymphoblastic leukemia in adult patients. , 2016, International journal of clinical pharmacology and therapeutics.

[7]  Guanwei Fan,et al.  ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells , 2016, Oncotarget.

[8]  Pornsiri Pitchakarn,et al.  Chemosensitizing effects of synthetic curcumin analogs on human multi-drug resistance leukemic cells. , 2016, Chemico-biological interactions.

[9]  E. Allender,et al.  CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro , 2016, Oncogene.

[10]  M. R. Ricciardi,et al.  The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia , 2015, Scientific Reports.

[11]  K. Stegmaier,et al.  Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML , 2015, Oncogene.

[12]  Jingjing Liu,et al.  Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells , 2015, Cell Death and Disease.

[13]  A. Kraft,et al.  PIM kinase (and Akt) biology and signaling in tumors. , 2015, Pharmacology & therapeutics.

[14]  J. Behravan,et al.  Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins. , 2015, Fitoterapia.

[15]  Y. Seo,et al.  Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin , 2015, Molecular medicine reports.

[16]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[17]  S. Dan,et al.  IVSE, isolated from Inula japonica,suppresses LPS-induced NO production via NF-κB and MAPK inactivation in RAW264.7 cells. , 2015, Life sciences.

[18]  S. Dan,et al.  In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA , 2014, Investigational New Drugs.

[19]  Quentin Liu,et al.  Inhibition of c-Myc Overcomes Cytotoxic Drug Resistance in Acute Myeloid Leukemia Cells by Promoting Differentiation , 2014, PloS one.

[20]  Jianlin Ren,et al.  Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway , 2014, BMC Complementary and Alternative Medicine.

[21]  S. Dan,et al.  In Vitro Antitumor Activity of Stellettin B, a Triterpene from Marine Sponge Jaspis stellifera, on Human Glioblastoma Cancer SF295 Cells , 2014, Marine drugs.

[22]  D. Xiao,et al.  Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1 , 2014, Cancer Cell International.

[23]  L. Ricci-Vitiani,et al.  Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide , 2014, BMC Cancer.

[24]  S. Dan,et al.  Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway. , 2013, Biochemical pharmacology.

[25]  J. Gimzewski,et al.  Nano-hole induction by nanodiamond and nanoplatinum liquid, DPV576, reverses multidrug resistance in human myeloid leukemia (HL60/AR) , 2013, International journal of nanomedicine.

[26]  Dexin Kong,et al.  In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells , 2013, International journal of molecular sciences.

[27]  X. Rui,et al.  Effect of Heparin-Derived Oligosaccharide on Vascular Smooth Muscle Cell Proliferation and the Signal Transduction Mechanisms Involved , 2012, Cardiovascular Drugs and Therapy.

[28]  A. Miyawaki,et al.  ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. , 2012, European journal of cancer.

[29]  Dexin Kong,et al.  JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. , 2012, Bioorganic & medicinal chemistry.

[30]  Zhe-Sheng Chen,et al.  Roles of sildenafil in enhancing drug sensitivity in cancer. , 2011, Cancer research.

[31]  H. Brown,et al.  Extensive sphingolipid depletion does not affect lipid raft integrity or lipid raft localization and efflux function of the ABC transporter MRP1. , 2010, The Biochemical journal.

[32]  T. Yamori,et al.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system , 2010, Acta Pharmacologica Sinica.

[33]  Dexin Kong,et al.  Advances in development of phosphatidylinositol 3-kinase inhibitors. , 2009, Current medicinal chemistry.

[34]  S. Dan,et al.  Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. , 2009, Biochemical and biophysical research communications.

[35]  Dexin Kong,et al.  Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy , 2008, Cancer science.

[36]  A M Martelli,et al.  Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia , 2006, Leukemia.

[37]  T. Sakai,et al.  Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. , 2006, Biochemical and biophysical research communications.

[38]  Xiukun Lin,et al.  Luteolin synergizes the antitumor effects of 5-fluorouracil against human hepatocellular carcinoma cells through apoptosis induction and metabolism. , 2016, Life sciences.

[39]  Dexin Kong,et al.  Inhibitory Effects of JEUD-38, a New Sesquiterpene Lactone from Inula japonica Thunb, on LPS-Induced iNOS Expression in RAW264.7 Cells , 2014, Inflammation.

[40]  Gordon B Mills,et al.  Functional proteomic profiling of AML predicts response and survival. , 2009, Blood.